

## Emcure Pharmaceuticals Launches Its OTC Portfolio With Galact Supplement For Breastfeeding Mothers

- *Emcure pharmaceuticals launches its Over-The-Counter (OTC) portfolio with the brand: **Galact***
- *Made from natural ingredients like Shatavari and 6 other herbs, Galact is a lactation supplement that helps boost the production of breast milk for mothers and is associated with improvement of immunity and IQ for the babies.*
- *In India only 64% mothers breastfeed their babies exclusively during first 6 months.*
- *Supports all mothers for exclusive breastfeeding for first 6 months (100%) as per WHO & UNICEF guidelines*
- 
- *Under the Galact brand, Emcure will be able to launch other products that address the various needs of the lactation phase*

**Mumbai, March 13, 2024:** Emcure Pharmaceuticals, an Indian pharmaceutical company with a strong focus on women's healthcare, announces its entry into the over-the-counter (OTC) market, with their product Galact. Prescribed by healthcare professionals for more than 20 years, Galact will now also be available as an over-the-counter (OTC) offering.

Enriched with the potency of *Shatavari* and six other herbs, Galact is meticulously formulated to boost breast milk production for mothers. *Shatavari* is also known to enhance baby's weight, sleep pattern, leading to better immunity, while a key ingredient, *Yashtimadhu*, helps in enhancing cognitive function, memory, and concentration, thereby assisting in improving baby's IQ. Following the launch of Galact, Emcure will be able to introduce a diverse array of OTC products catering to the unique needs of women.

Speaking on the occasion, **Ms. Namita Thapar, Whole-time Director, Emcure Pharmaceuticals** said, "Emcure has always focused on awareness, access, and affordability to strengthen women's health in India. The launch of Galact marks our efforts to redefine and further elevate the standard of women's health solutions. Our foray into the OTC segment focuses on empowering women across various life stages, starting with a portfolio tailored for their lactation journey. In India, only 64% of mothers breastfeed their babies exclusively in the first 6 months. By making Galact available over the counter, Emcure aims to sensitise all mothers to practice exclusive breastfeeding for the first 6 months in line with the WHO and UNICEF breastfeeding guidelines. Emcure plans to introduce more products under the Galact brand."

The company has a deep ethos of generating awareness around women's health issues like anemia, menstruation, and breastfeeding. With the launch of its renewed and redesigned Galact brand, Emcure aims to further the cause of breastfeeding and promote optimal nutrition for infants.

### Disclaimer

*"Emcure Pharmaceuticals Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, an initial public offering of its equity shares and has filed a draft red herring prospectus dated December 16, 2023 ("DRHP") with the Securities and Exchange Board of India ("SEBI"). The DRHP is available on the websites of the Company at [www.emcure.com](http://www.emcure.com), SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), the book running lead managers, Kotak Mahindra Capital Company Limited, Axis Capital Limited, Jefferies India Private Limited, and JP Morgan India Private Limited at <https://investmentbank.kotak.com>, [www.axiscapital.co.in](http://www.axiscapital.co.in), [www.jefferies.com](http://www.jefferies.com) and [www.jpmipl.com](http://www.jpmipl.com), respectively, and the stock exchange(s) at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com), respectively. Investors should note that investment in equity shares involves a high degree of risk and for details*

*refer to the Red Herring Prospectus, including the section titled "Risk Factors" of the Red Herring Prospectus when available. Potential investors should not rely on the DRHP for making any investment decision."*

**About Emcure Pharmaceuticals Ltd:**

Emcure Pharmaceuticals Ltd. (EPL) is an Indian pharmaceutical company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. . Established in 1981, EPL is ranked as the 13th largest pharma company in India in terms of Domestic Sales for MAT September 2023.

To know more about Emcure, please visit: <https://www.emcure.com/>

Follow us on LinkedIn: <https://www.linkedin.com/company/emcure-pharmaceuticals-limited/>

Reference Links:

1: [UNICEF India figures](#)

2: [National family health survey \(NFHS – 2019\)](#)